Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 5/20 | 0.58 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.50 |
| ▸ | ICMT | O60725 | 2/20 | 0.50 |
| ▸ | ALB | P02768 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | THRA | P10827 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10352448 | 1.00 | KDM5A (0.58) | KDM5APHF8ICMTALBKDM4C | |
| SCHEMBL16922400 | 1.00 | KDM5A (0.58) | KDM5APHF8ICMTALBKDM4C | |
| SCHEMBL8954715 | 1.00 | KDM5A (0.58) | KDM5APHF8ICMTALBKDM4C | |
| SCHEMBL19032589 | 0.98 | KDM5A (0.56) | KDM5APHF8ICMTALBKDM4C | |
| SCHEMBL26465315 | 0.98 | KDM5A (0.57) | KDM5APHF8ICMTALBKDM4C | |
| SCHEMBL13903730 | 0.92 | KDM5A (0.58) | KDM5APHF8ICMTALBKDM4C | |
| SCHEMBL28439075 | 0.92 | KDM5A (0.54) | KDM5APHF8ICMTALBKDM4C | |
| Hexadecanoic Acid Methyl Ester SCHEMBL28398014 | 0.92 | KDM5A (0.58) | KDM5APHF8ICMTALBKDM4C | |
| SCHEMBL28399246 | 0.92 | KDM5A (0.58) | KDM5APHF8ICMTALBKDM4C | |
| SCHEMBL28399964 | 0.92 | KDM5A (0.58) | KDM5APHF8ICMTALBKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638678-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-4036079-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ModernaTX, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-06-03 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| WO-2018232120-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-22 | — | — | US | disclosed |
| EP-3394030-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-0323409-B1 | Polyolefin compositions stabilized with long chain N,N-dialkylhydroxylamines | CIBA GEIGY AG (CH) | 1996-01-03 | — | — | EP | disclosed |
| EP-0286596-B1 | Use of n,n-dialkylhydroxylamines and their preparation | CIBA GEIGY AG (CH) | 1995-06-21 | — | — | EP | disclosed |
| US-4876300-A | RESISTANCE TO EXTRACTION | CIBA-GEIGY CORPORATION (US) | 1989-10-24 | — | — | US | disclosed |
| EP-0323409-A2 | Polyolefin compositions stabilized with long chain N,N-dialkylhydroxylamines | CIBA-GEIGY AG (CH) | 1989-07-05 | — | — | EP | disclosed |
| US-4782105-A | POLYTHIOETHERS AND UNSATURATED ELASTOMERS | CIBA-GEIGY CORPORATION (US) | 1988-11-01 | — | — | US | disclosed |
| EP-0286596-A2 | Use of n,n-dialkylhydroxylamines and their preparation | CIBA-GEIGY AG (CH) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885PHF8 3001/4885ICMT 3596/4885 |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885PHF8 3001/4885ICMT 3596/4885 |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885PHF8 3001/4885ICMT 3596/4885 |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885PHF8 3001/4885ICMT 3596/4885 |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885PHF8 3001/4885ICMT 3596/4885 |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | KDM5A 4758/4885PHF8 3001/4885ICMT 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.